Sign in

    Chris Kallos • MST Access

    Chris Kallos is a Senior Research Analyst at MST Access, specializing in equity research with a strong focus on the healthcare and biotech sectors. He covers companies such as Healius, Monash IVF Group, Polynovo, and Integral Diagnostics, providing detailed investment analysis and industry insights. With a career spanning over two decades, Chris has held analyst roles at firms including UBS and Morgans Financial Limited before joining MST Access in 2022, and he is known for a robust research performance, including a top-three ranking on TipRanks for healthcare stock calls in Australia. Chris holds a Bachelor of Commerce and Bachelor of Laws, is a CFA Charterholder, and maintains relevant securities advisory qualifications.

    Chris Kallos's questions to AVITA Medical Inc (RCEL) leadership

    Chris Kallos's questions to AVITA Medical Inc (RCEL) leadership • Q1 2025

    Question

    Chris Kallos from MST Access sought clarification on the current status of the vitiligo initiative, specifically asking about the company's efforts to pursue reimbursement and whether discussions with agencies have been suspended.

    Answer

    CEO James Corbett explained that AVITA has paused commercial investment in the vitiligo indication due to the high uncertainty of achieving reimbursement in the office-based setting. He emphasized that the company is redirecting resources to the larger acute wound care market. While not an "absolute zero" in terms of discussions, he advised that no revenue from vitiligo should be included in future estimates until a defined path forward is announced.

    Ask Fintool Equity Research AI

    Chris Kallos's questions to AVITA Medical Inc (RCEL) leadership • Q3 2024

    Question

    Chris Kallos of MST Access inquired about feedback from European distributors on RECELL GO, the impact of the CE Mark delay on launch timelines, and any changes to the vitiligo initiative timeline.

    Answer

    CEO Jim Corbett reported positive feedback from European distributors who are eager for RECELL GO due to its reduced training requirements. He expects the CE Mark in Q1 2025 despite delays, attributing the lag to systemic issues with notified bodies. He also reiterated that the vitiligo timeline is unchanged, with significant revenue not expected until 2026 pending payer coverage.

    Ask Fintool Equity Research AI